Get the Stockscreener App
2.845
9.00%
0.235
After Hours:
5.15
2.305
+81.02%
Lunai Bioworks Inc stock is traded at $2.845, with a volume of 3.93M.
It is up +9.00% in the last 24 hours and up +38.27% over the past month.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
See More
Previous Close:
$2.61
Open:
$2.66
24h Volume:
3.93M
Relative Volume:
1.57
Market Cap:
$12.90M
Revenue:
-
Net Income/Loss:
$-128.28M
P/E Ratio:
-0.0464
EPS:
-61.2898
Net Cash Flow:
$-5.26M
1W Performance:
+24.24%
1M Performance:
+38.27%
6M Performance:
-66.45%
1Y Performance:
+0.00%
1-Day Range:
$2.53
$2.9194
1-Week Range:
$2.25
$2.9194
52-Week Range:
$1.2104
$13.28
Lunai Bioworks Inc Stock (LNAI) Company Profile
Name
Lunai Bioworks Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
2.845 | 11.83M | 0 | -128.28M | -5.26M | -61.29 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lunai Bioworks Inc Stock (LNAI) Latest News
LNAI Should I Buy - Intellectia AI
Why Is This Micro-Cap Biotech Stock Up 150% Today? - Stocktwits
Lunai Bioworks Inc Stock Short Interest Rises to 62.94% - Quiver Quantitative
Top Lunai Bioworks (LNAI) Competitors 2026 - MarketBeat
LNAI Q1 2026 Earnings: Pre-Revenue Biotech Reports EPS of -$0.08, Shares AdvanceEarnings Revision Downgrade - newsline.com
LNAI Stock Chart | LUNAI BIOWORKS INC (NASDAQ:LNAI) - ChartMill
LNAI Q1 2026 Earnings: EPS Loss in Line with Expectations as Biotech Advances Pipeline; Stock Surges 16%Slow Growth Warning - The Legal Advocate
Lunai Bioworks Inc. (LNAI) Q1 2026 Earnings: Early-Stage Biotech Posts Narrower-Than-Expected Loss, Shares Surge Over 16%Revenue Beat Analysis - The Legal Advocate
Lunai Bioworks partners with BrainStorm on neurology drug discovery - Investing.com UK
Lunai Bioworks and BrainStorm launch foundation for neurological diseases - TipRanks
Lunai Bioworks Inc. and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's And Rare Epilepsy AI Discovery Collaboration - marketscreener.com
Lunai Bioworks partners with BrainStorm on neurology drug discovery By Investing.com - Investing.com Australia
AI and human brain organoids join forces on Parkinson's, rare epilepsy - Stock Titan
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration - PR Newswire
Lunai Bioworks, Inc. Cash Flow – LS:A42CL6 - TradingView
Pretax income of Lunai Bioworks, Inc. – LS:A42CL6 - TradingView
Lunai Bioworks Company Profile & Introduction - Moomoo
Lunai Bioworks, Inc. Financial Disclosures & SEC Filings - TradingView
Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle - Bez Kabli
Lunai Bioworks to implement 1-for-8 reverse stock split - MSN
Lunai Bioworks Inc. (LNAI) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider-Than-Expected Loss Amid Pipeline ProgressEnergy Earnings Report - Newser
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock - Quantisnow
Lunai Bioworks federal judge grants Lunai Bioworks expedited discovery to identify "naked" short sellers - marketscreener.com
Lunai Bioworks Federal Judge Grants Lunai Bioworks Expedited Discovery To Identify "Naked" Short Sellers - TradingView
Lunai Bioworks Inc. (LNAI) Q1 2026 Earnings: Early-Stage Biotech Delivers Strategic Progress Despite GAAP LossFinancial Summary - The Legal Advocate
Lunai Bioworks (LNAI) Q1 2026 Earnings: As Expected, No SurprisesEarnings Volatility Report - Newser
Lunai Bioworks Announces 1-for-8 Reverse Stock Split - The Globe and Mail
Lunai Bioworks Announces 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Lunai Bioworks, Inc. announces reverse stock split - marketscreener.com
Lunai Bioworks stock falls after reverse split announcement By Investing.com - Investing.com South Africa
Lunai Bioworks announces 1-for-8 reverse stock split By Investing.com - Investing.com Australia
Lunai Bioworks announces 1-for-8 reverse stock split - Investing.com
Lunai Bioworks stock falls after reverse split announcement - Investing.com India
Lunai Bioworks, Inc. Announces Reverse Stock Split - TradingView
Lunai Bioworks announces 1-for-8 reverse stock split to boost Nasdaq compliance, shares cut to ~4.53M - TradingView
Lunai Bioworks (NASDAQ: LNAI) plans 1-for-8 reverse split to meet Nasdaq price rule - Stock Titan
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT - PR Newswire
Dickinson Wright And Fox Rothschild Join Forces To File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers Of Lunai Common Stock - marketscreener.com
Lunai Bioworks Inc Stock (LNAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):